Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fusion Pharmaceuticals (FUSN – Research Report), Caribou Biosciences (CRBU – Research Report) and Neurogene (NGNE – Research Report).
Fusion Pharmaceuticals (FUSN)
Fusion Pharmaceuticals received a Hold rating and a $21.00 price target from Leerink Partners analyst Faisal Khurshid today. The company’s shares closed last Monday at $10.64.
Khurshid has an average return of
According to TipRanks.com, Khurshid is ranked #351 out of 8752 analysts.
Currently, the analyst consensus on Fusion Pharmaceuticals is a Strong Buy with an average price target of $15.89.
See the top stocks recommended by analysts >>
Caribou Biosciences (CRBU)
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Caribou Biosciences today and set a price target of $24.00. The company’s shares closed last Monday at $5.23.
According to TipRanks.com, Burns has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Caribou Biosciences with a $23.80 average price target, representing a 328.1% upside. In a report issued on March 11, RBC Capital also maintained a Buy rating on the stock with a $19.00 price target.
Neurogene (NGNE)
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Neurogene today and set a price target of $55.00. The company’s shares closed last Monday at $37.55, close to its 52-week high of $40.18.
According to TipRanks.com, Kapoor has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Neurogene is a Strong Buy with an average price target of $49.50, representing a 28.6% upside. In a report issued on March 6, TD Cowen also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FUSN:
- Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
- Fusion Pharmaceuticals Inc (FUSN) Q4 Earnings Cheat Sheet
- 3 Best Stocks to Buy Now, 3/5/2024, According to Top Analysts
- Fusion Pharmaceuticals price target raised to $16 from $12 at RBC Capital
- Fusion licensing agreement ‘hugely positive,’ says B. Riley
